Ligand Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ligand Pharma (LGND) Tops Q3 EPS by 29c, Revenues Beat; Raises FY18 Revenue Guidance Above Consensus
November 8, 2018 8:09 AM ESTLigand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.32, $0.29 better than the analyst estimate of $1.03. Revenue for the quarter came in at $45.66 million versus the consensus estimate of $41.7 million.
This quarter was marked by several events that demonstrate the strength of Ligands business... More
